ASH: Adding Subcutaneous Daratumumab Slows Advanced Multiple Myeloma
TUESDAY, Dec. 8, 2020 — For patients with relapsed/refractory multiple myeloma (RRMM), subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) reduces
Read more
ASH develops practice guidelines for venous thromboembolism
(HealthDay)—The American Society of Hematology (ASH) has developed new guidelines for the treatment of venous thromboembolism (VTE); the clinical practice
Read more